These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38608143)

  • 21. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
    Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
    Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
    Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
    [No Abstract]   [Full Text] [Related]  

  • 26. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.
    Adamson RT
    Am J Manag Care; 2013 Dec; 19(19 Suppl):s398-404. PubMed ID: 24494721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of molecular analyses in the era of personalized therapy for advanced NSCLC.
    Tanner NT; Pastis NJ; Sherman C; Simon GR; Lewin D; Silvestri GA
    Lung Cancer; 2012 May; 76(2):131-7. PubMed ID: 22176813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized targeted therapy in advanced non-small cell lung cancer.
    Ma PC
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
    Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW.
    Kumar M; Sarkar A
    Exp Oncol; 2022 May; 44(1):7-16. PubMed ID: 35548961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
    Cronemberger E; Baldotto C; Marinho F; De Marchi P; Araújo LH; Franke F; Salles P; Calabrich A; Almeida T; Custodio MG; Maria AS; Pereira MH; Castro G
    Clinics (Sao Paulo); 2020; 75():e1777. PubMed ID: 33084767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
    Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
    JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
    Liu W; Huo G; Chen P
    Front Immunol; 2022; 13():909027. PubMed ID: 35799785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
    Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
    Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
    Chen L; Smith DA; Somarouthu B; Gupta A; Gilani KA; Ramaiya NH
    AJR Am J Roentgenol; 2019 Nov; 213(5):1047-1058. PubMed ID: 31361530
    [No Abstract]   [Full Text] [Related]  

  • 38. [Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of 
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].
    Xiao T; Bao J; Liu X; Huang H; Zhou H
    Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):756-763. PubMed ID: 36167462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
    Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
    Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.
    Palazzo LL; Sheehan DF; Tramontano AC; Kong CY
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):926-934. PubMed ID: 30787053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.